Disseminated sclerosis (MS) - symptoms, causes, examinations and treatment

Multiple sclerosis (MS, derived from Latin *sclerosis multiplex*) constitutes a complex, progressive autoimmune disorder characterized by inflammatory-demyelinating pathology that selectively targets the central nervous system. The underlying pathogenic mechanism involves the gradual degradation of myelin sheaths surrounding axons—the nerve fibers responsible for electrical impulse conduction—resulting in signal transmission delays and, in advanced stages, complete cessation of neuronal communication. The clinical course of MS is highly heterogeneous, marked by alternating phases of exacerbations (relapses) and remissions, which vary in severity, duration, and degree of symptom reversibility. The term *multiple sclerosis* refers to the disseminated, sclerotic lesions (plaques) within the brain and spinal cord that develop as a consequence of chronic inflammation. Epidemiologically, MS exhibits a distinct geographic pattern: it is uncommon in tropical regions, whereas temperate climates demonstrate higher prevalence rates, predominantly affecting young adults (ages 20–40) with a marked female predominance (female-to-male ratio approximately 2:1 to 3:1).

Multiple sclerosis presents with an exceptionally diverse array of symptoms, the severity of which can vary substantially depending on the individual disease trajectory. One of the initial—yet frequently overlooked—manifestations is a persistent sense of fatigue that arises independently of physical or mental exertion, remaining relentless despite rest. Among the visual disturbances, retrobulbar optic neuritis is particularly prominent, characterized by blurred or dimmed vision that, in advanced stages, may progress to irreversible blindness. Progressive sensory and motor impairments significantly diminish patients’ quality of life and, in severe cases, culminate in complete functional dependency. Neurological complications further encompass dysarthria and dysphagia, diffuse musculoskeletal pain, and neuropathic pain syndromes described as burning, chronic, and refractory to conventional treatments. Additionally, the disease is often associated with cognitive decline, depressive episodes, and social withdrawal. Autonomic nervous system dysfunction may result in urinary incontinence, constipation, and an inability to regulate basic physiological processes. The *Expanded Disability Status Scale* (EDSS) is employed to assess the degree of disability and symptom severity in MS, facilitating a structured evaluation of disease progression and its impact on patient functionality.

The etiology of multiple sclerosis remains a multifaceted and not yet fully elucidated phenomenon, shaped by an interplay of interconnected determinants. A key epidemiological observation is the pronounced correlation between disease risk and geographic latitude, with individuals residing in higher-latitude regions—particularly in the Northern Hemisphere—demonstrating a statistically significant elevation in incidence rates. This pattern suggests a potential influence of environmental variables such as sunlight exposure, vitamin D levels, or exposure to specific pathogens. Another critical factor is genetic predisposition: research confirms an increased risk among individuals with a family history of the disease, particularly when MS is present in siblings or close relatives, indicating a hereditary susceptibility. Furthermore, geographic distribution analyses reveal higher prevalence rates in populations of European descent, which may reflect both genetic and environmental contributions. The age of onset typically falls within the 20–30-year range, with a marked female predominance, hinting at the involvement of sex-dependent hormonal or immunological mechanisms. Hypotheses regarding the autoimmune origins of MS, including the role of dysregulated immune responses and the potential contribution of viral infections (e.g., Epstein-Barr virus), remain subjects of ongoing investigation, though conclusive causal evidence has yet to be established.

Among the primary techniques for visualizing pathological alterations within the nervous system are computed tomography (CT) scans and magnetic resonance imaging (MRI). These modalities facilitate precise tracking of disease progression rates, pinpointing demyelinated lesions, and generating forecasts regarding long-term clinical trajectories. Another pivotal diagnostic tool is cerebrospinal fluid (CSF) analysis, which enables detection of distinctive protein biomarkers, such as oligoclonal IgG bands. Additionally, evoked potential studies—including visual (VEP), auditory (BAEP), and somatosensory (SSEP) assessments—can provide early indicators of neurological impairment, with deviations from baseline often correlating with progressive nerve fiber degeneration.

To date, no therapeutic intervention exists that can halt the progression of multiple sclerosis or achieve a definitive cure. Nevertheless, contemporary medicine provides an array of pharmacological and non-pharmacological strategies that substantially enhance patients' quality of life while significantly decelerating the advancement of pathological alterations within the central nervous system. Corticosteroid medications facilitate partial recovery of functions compromised during acute exacerbations, whereas disease-modifying therapies—most notably the widely prescribed interferon beta—alter the clinical trajectory of MS by reducing both the frequency and severity of relapses. In instances of highly aggressive, rapidly progressive disease variants, immunosuppressive agents are frequently deployed to mitigate the aberrant autoimmune response. An indispensable component of comprehensive management is structured physical and neuropsychological rehabilitation, which demonstrably enhances patients' functional independence and overall well-being. Equally critical are lifestyle modifications: a nutrient-dense diet rich in omega-3 fatty acids and antioxidants, tailored physical activity regimens, effective stress-reduction techniques, and vigilant avoidance of infectious triggers known to precipitate relapses. Multiple sclerosis represents one of the most formidable challenges in modern neurology—a relentlessly progressive disorder culminating in cumulative neurological disability. While no curative treatment exists, early implementation of symptomatic and disease-modifying therapies can substantially postpone the emergence of additional deficits. The condition predominantly affects young adults during their most productive years, with initial manifestations often being subtle and nonspecific, thereby delaying accurate diagnosis. Beyond its devastating physical consequences, MS exacts profound psychological and social tolls, progressively marginalizing affected individuals from professional and social engagement.